Patents Issued in June 15, 2017
-
Publication number: 20170166598Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.Type: ApplicationFiled: May 13, 2015Publication date: June 15, 2017Inventors: Wei-Sheng HUANG, Feng LI, David C. DALGARNO, Yongjin GONG, Alexey V. ISHCHENKO, Anna KOHLMANN, William C. SHAKESPEARE, Angela V. WEST, Yongjin XU, Willmen YOUNGSAYE, Yun ZHANG, Tianjun ZHOU, Xiaotian ZHU
-
Publication number: 20170166599Abstract: Provided is a metal complex excellent in light emission stability. The metal complex is represented by the formula (1): wherein M represents an iridium atom or the like, n1 represents an integer of 1 to 3, n2 represents an integer of 0 to 2, E2 to E4 represent a nitrogen atom or a carbon atom where two selected from among E2 to E4 are nitrogen atoms and the remaining one is a carbon atom, R1 represents an aryl group or the like, R2 and R3 represent a hydrogen atom, an alkyl group, an aryl group or the like, the ring B represents a triazole ring, the ring A represents an aromatic hydrocarbon ring or the like, and A1-G1-A2 represents an anionic bidentate ligand.Type: ApplicationFiled: July 2, 2015Publication date: June 15, 2017Applicant: Sumitomo Chemical Company, LimitedInventors: Taichi ABE, Kohei ASADA, Kazuei OHUCHI
-
Publication number: 20170166600Abstract: The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof, a stereoisomer or a mixture of stereoisomers in any ratio, or a water-soluble derivative, as well as to methods for preparing same and to the use thereof, in particular in the treatment of cancer.Type: ApplicationFiled: October 30, 2014Publication date: June 15, 2017Inventors: Gerard Jaouen, Pascal Pigeon, Siden Top
-
Publication number: 20170166601Abstract: The present invention generally relates to systems and methods for pressure driven flow crystallization. In some embodiments, the system comprises a comprising a cavity and a mixing mechanism. In some embodiments, one or more inlets facilitate the transfer of one or more reagent streams to the cavity. In some such embodiments, the mixing mechanism mixes the first and second reagent streams such that a continuous crystallization and/or generation of a product (e.g., solid particles) in the fluid.Type: ApplicationFiled: December 8, 2016Publication date: June 15, 2017Applicant: Massachusetts Institute of TechnologyInventors: Allan S. Myerson, Marcus O'Mahony, Torsten Stelzer, Yuqing Cui
-
Publication number: 20170166602Abstract: The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.Type: ApplicationFiled: July 22, 2015Publication date: June 15, 2017Applicants: NuCana Biomed Limited, Laurus Labs Private Ltd.Inventors: Venkata Lakshmi Narasimha Rao Dammalapati, Mani Bushan Kotala, Shankar Madhavaram
-
Publication number: 20170166603Abstract: Provided herein are heptamethine cyanine dyes having a large Stokes shift, and the salts and conjugates thereof. Also provided are methods of using and making such large Stokes shift dyes as fluorescence resonance energy transfer (FRET) acceptors or donors.Type: ApplicationFiled: February 21, 2017Publication date: June 15, 2017Inventors: Yi-Zhen HU, Hee Chol KANG
-
Publication number: 20170166604Abstract: The present invention is related to a method for the preparation of a polyalkoxylated nucleic acid molecule, wherein the method comprises separating the polyalkoxylated nucleic acid molecule from a mixture of nucleic acid molecules, wherein the mixture of nucleic acid molecules comprises the polyalkoxylated nucleic acid molecule and a non-polyalkoxylated nucleic acid molecule, and wherein the polyalkoxylated nucleic acid molecule is separated from the non-polyalkoxylated nucleic acid molecule by precipitating the polyalkoxylated nucleic acid molecule from the mixture.Type: ApplicationFiled: February 3, 2015Publication date: June 15, 2017Applicant: NOXXON Pharma AGInventor: Lucas Bethge
-
Publication number: 20170166605Abstract: A hydroprocessing catalyst has been developed. The catalyst is a unique transition metal molybdotungsten oxy-hydroxide material. The hydroprocessing using the transition metal molybdotungsten oxy-hydroxide material may include hydrodenitrification, hydrodesulfurization, hydrodemetallation, hydrodesilication, hydrodearomatization, hydroisomerization, hydrotreating, hydrofining, and hydrocracking.Type: ApplicationFiled: December 13, 2016Publication date: June 15, 2017Inventors: Stuart Miller, Susan C. Koster
-
Publication number: 20170166606Abstract: The present invention relates to a device for separating and/or isolating substances in or from a mixture with improved utilization of the capacity of chromatographic media, the device comprising a first chromatography system, a second chromatography matrix downstream of the first chromatography system, and a sensor for detecting the substances present in the fluid. Furthermore, the present invention relates to both the use of said device and a method for separating and/or isolating substances in or from a mixture in a fluid.Type: ApplicationFiled: May 12, 2015Publication date: June 15, 2017Inventors: Louis Villain, Jörg Mittelstät, Ana Raquel Santos De Matos Fortuna, Katrin Töppner
-
Publication number: 20170166607Abstract: Embodiments herein provide methods of purifying monoclonal and polyclonal anti-bodies (e.g., immunoglobulins) from biological fluids, such as cell lysates, cell supernatant and ascites fluids, using small molecule affinity chromatography. Various embodiments disclose a class of small molecules that selectively bind a nucleotide binding site that is inherent to all immunoglobulins, and in various embodiments, methods are disclosed that use one of these small molecules as a capture molecule in small molecule affinity chromatography. In some embodiments, the small molecule may be an indole, and in particular embodiments, the small molecule may be indole-3-butyric acid.Type: ApplicationFiled: February 17, 2017Publication date: June 15, 2017Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Zihni Basar Bilgicer, Tanyel Kiziltepe Bilgicer, Nathan Joseph Alves, Jonathan Darryl Ashley, Michael William Handlogten
-
Publication number: 20170166608Abstract: The invention is directed to a Ca2+ precipitable polypeptide tags and cassettes useful for purification of molecules from heterogeneous samples. The invention also relates to methods for bioseparation of molecules comprising Ca2+ precipitable tags and cassettes.Type: ApplicationFiled: December 13, 2016Publication date: June 15, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Scott Banta, Oren Shur
-
Publication number: 20170166609Abstract: The present invention relates to a peptide promoting angiogenesis and novel use thereof. More particularly, the invention relates to peptides promoting angiogenesis, and the use of the peptide for promoting angiogenesis and preventing or treating angiogenesis-related disease. The peptide of the present invention have an excellent effect on promoting angiogenesis. Accordingly, it is useful for preventing or treating angiogenesis-related disease and for preparing regeneration of skin flap, wound and burn healing, implantation of artificial skin and preparation of blood vessels for transplantation.Type: ApplicationFiled: February 16, 2017Publication date: June 15, 2017Inventors: Dae Ho CHO, Sa Ik BANG, Jeong Min PARK, Sun Young YOON, Sang Yoon KIM, Ha Rum LEE, Yoo Rim PARK, Juah SON
-
Publication number: 20170166610Abstract: In some aspects, the present invention provides methods of treating a subject in need of treatment for neuropathic pain, the method comprising administering a compstatin analog to the subject. In some embodiments, the compstatin analog is administered parenterally, e.g., intravenously.Type: ApplicationFiled: July 13, 2016Publication date: June 15, 2017Inventors: Cedric Francois, Pascal Deschatelets
-
Publication number: 20170166611Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.Type: ApplicationFiled: February 17, 2017Publication date: June 15, 2017Applicant: Rutgers, The State University of New JerseyInventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
-
Publication number: 20170166612Abstract: A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.Type: ApplicationFiled: February 22, 2017Publication date: June 15, 2017Inventors: Zhongqi SHAO, Junqiang LI, Rong JIANG, Mingming YANG, Tao ZHU, Helen Huihua MAO, Xuefeng YU
-
Publication number: 20170166613Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.Type: ApplicationFiled: February 22, 2017Publication date: June 15, 2017Inventors: Kirk Schnorr, Randall Kramer
-
Publication number: 20170166614Abstract: The present invention relates to an esculentin-2CHa peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia.Type: ApplicationFiled: February 2, 2015Publication date: June 15, 2017Applicant: UNIVERSITY OF ULSTERInventors: Yasser Abdel-Wahab, Peter Flatt, Opeolu Ojo, Michael J. Conlon
-
Publication number: 20170166615Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: December 7, 2016Publication date: June 15, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
-
Publication number: 20170166616Abstract: The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides.Type: ApplicationFiled: January 6, 2017Publication date: June 15, 2017Applicants: Rigshospitalet, Kobenhavns Universitet, Syddansk UniversitetInventors: Peter Garred, Tina Hummelshoj Glue, Mikkel-Ole Skjodt
-
Publication number: 20170166617Abstract: This invention relates generally to a codon optimized nucleic acid encoding a retinitis pigmentosa GTPase regulator (RPGR) protein. The nucleic acid has enhanced stability during plasmid production relative to a wildtype cDNA encoding the RPGR protein. The invention also relates to expression cassettes, vectors, and host cells comprising the codon optimized nucleic acid. Methods for preparing a recombinant adeno-associated (rAAV) expression vector comprising the codon optimized nucleic acid sequence are also provided. The nucleic acids, expression cassettes, vectors, and host cells provided may be useful in the large scale production of rAAV expression vectors for gene therapy applications.Type: ApplicationFiled: November 23, 2016Publication date: June 15, 2017Applicant: Applied Genetic Technologies CorporationInventors: Guo-Jie Ye, Jilin Liu
-
Publication number: 20170166618Abstract: The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders.Type: ApplicationFiled: April 3, 2015Publication date: June 15, 2017Applicant: NOVARTIS AGInventors: David GLASS, Shou-Ih HU
-
Publication number: 20170166619Abstract: The invention relates to a method for producing a polypeptide which is modified with an organic group, wherein a bioactive polypeptide is covalently bound to an organic group that comprises a backbone structure having aromatic side chains, thereby forming a modified polypeptide which is constituted of the bioactive polypeptide and the group having aromatic side chains. At least one of the aromatic side chains of the group is subjected to chemical or enzymatic hydroxylation.Type: ApplicationFiled: December 16, 2016Publication date: June 15, 2017Inventor: Herbert P. Jennissen
-
Publication number: 20170166620Abstract: The invention is directed to cancer immunotherapy. The invention is specifically directed to the induction of innate or adaptive antitumor immunity initiated by the administration of targeted IL-12 molecules preferably in conjunction with IL-2 and/or IL-7 to a cancer patient, who suffers from cancer of the muscle, bone, nerves, cartilage, tendons, blood vessels, etc., preferably from sarcoma. The invention is specifically related to the use of IL-12 in form of the specific immunoglobulin cytokine fusion protein called NHS-IL12, preferably in combination with a form of IL-2 and/or IL-7 exhibiting prolonged pharmacokinetics for the treatment of said cancer diseases.Type: ApplicationFiled: February 18, 2015Publication date: June 15, 2017Applicant: Merck Patent GmbHInventors: Wolfgang Strittmatter, Rupert Handgretinger, Karin Schilbach-Stueckle
-
Publication number: 20170166621Abstract: The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions.Type: ApplicationFiled: August 26, 2016Publication date: June 15, 2017Applicant: NOVARTIS AGInventors: Brian R. BOETTCHER, Shari Lynn CAPLAN, Susan E. CELLITTI, Douglas S. DANIELS, Norio HAMAMATSU, Bernhard Hubert GEIERSTANGER, Stuart LICHT, Andreas LOEW, Stephen Craig WELDON
-
Publication number: 20170166622Abstract: Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.Type: ApplicationFiled: January 30, 2017Publication date: June 15, 2017Inventors: Patrick BAEUERLE, Gregory SIECZKIEWICZ, Robert HOFMEISTER
-
Publication number: 20170166623Abstract: The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.Type: ApplicationFiled: July 24, 2015Publication date: June 15, 2017Inventors: Sophie AGAUGUE, Lorenzo TIBALDI, Klervi EVEN-DESRUMAUX, Dmitry TRUBETSKOY, Franck PEREZ, Sebastian AMIGORENA, Cécile BAUCHE
-
Publication number: 20170166624Abstract: Certain embodiments are directed to TGF-? inhibitors EUc and REUc. EUc is generated by removing the non-binding N-terminal subdomain from the TGF-? type III receptor, and REUc is generated by fusing together the binding domains of the TGF-? type II (RII or R) and type III receptor (RIII or EU) by a flexible linker and by removing the non-binding N-terminal subdomain from the TGF-? type III receptor.Type: ApplicationFiled: July 14, 2015Publication date: June 15, 2017Inventors: Andrew Hinck, LuZhe Sun, Christian Zwieb
-
Publication number: 20170166625Abstract: The present invention relates to soluble monomeric Anti-Mullerian Hormone Receptor type II (AMHRII) fusion proteins and uses thereof, in particular for detection or quantification of the bioactive cleaved form of Anti-Müillerian Hormone in a sample. In particular, the present invention relates to a soluble monomeric AMHRII fusion protein wherein one AMHRII extracellular domain is fused to a heterologous polypeptide. A further aspect of the present invention relates to a method for detecting or quantifying the presence of bioactive cleaved AMH in a sample, said method comprising contacting the sample with a soluble monomeric AMHRII fusion protein of the invention.Type: ApplicationFiled: February 2, 2015Publication date: June 15, 2017Inventors: Nathalie DI CLEMENTE, Richard CATE
-
Publication number: 20170166626Abstract: The invention relates to an albumin-purification method comprising a step consisting in subjecting an aqueous albumin solution, with a concentration of between 15 g/l and 80 g/l and a pH of not less than 7, to nanofiltration in a temperature range of between 15 DEG C and 55 DEG C. The invention also relates to: a virally-safe aqueous albumin solution which can be obtained using the inventive method and in which the sites for the transport and binding of the active therapeutic ingredients of the albumin are available; and an albumin composition for therapeutic use, which is obtained by adapting the albumin solution that is intended for clinical use.Type: ApplicationFiled: February 27, 2017Publication date: June 15, 2017Applicant: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOT ECHNOLOGIESInventors: Paul BOULANGE, Sami CHTOUROU, Stephane BOYER, Roland SCHMITTHAEUSLER, Bruno PADRAZZI
-
Publication number: 20170166627Abstract: The present application provides fibronectin based scaffold proteins associated with improved stability. The application also relates to stable formulations of fibronectin based scaffold proteins and the use thereof in diagnostic, research and therapeutic applications. The application further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising such polynucleotides.Type: ApplicationFiled: December 20, 2016Publication date: June 15, 2017Inventors: Ray CAMPHAUSEN, John O'LOUGHLIN, Bernice YEUNG, Yihong ZHANG
-
Publication number: 20170166628Abstract: The present invention concerns VLPT immunoreactive compositions for E. chaffeensis and compositions related thereto, including vaccines, antibodies, polypeptides, peptides, and polynucleotides. In particular, epitopes for E. chaffeensis VLPT are disclosed.Type: ApplicationFiled: February 23, 2017Publication date: June 15, 2017Applicant: Research Development FoundationInventors: Jere W. McBRIDE, Tian LUO
-
Publication number: 20170166629Abstract: Anti-microbial monoclonal antibodies and variant antibodies having a heavy chain constant regions with at least one amino acid substitution are provided. Such antibodies may be used to prevent or treat microbial infections.Type: ApplicationFiled: August 15, 2016Publication date: June 15, 2017Inventor: Nicholas B. LYDON
-
Publication number: 20170166630Abstract: The invention relates to humanized anti-human Factor D monoclonal antibodies, their nucleic acid and amino acid sequences, the cells and vectors that harbor these antibodies and their use in the preparation of compositions and medicaments for treatment of diseases and disorders associated with excessive or uncontrolled complement activation. These antibodies are useful for diagnostics, prophylaxis and treatment of disease.Type: ApplicationFiled: July 29, 2016Publication date: June 15, 2017Inventors: Ling-Ling An, Sek Chung Fung, Robert F. Kelley, Henry B. Lowman, Sanjaya Singh, Herren Wu
-
Publication number: 20170166631Abstract: Provided are novel human-derived anti-huntingtin (HTT) antibodies and biotechnological derivatives thereof, preferably capable of binding mutated and/or aggregated HTT species and or fragments thereof, as well as methods related thereto. The human-derived anti-HTT antibodies and biotechnological derivatives can be used in pharmaceutical and diagnostic compositions for HTT targeted immunotherapy of Huntington Disease and diagnosis thereof.Type: ApplicationFiled: July 29, 2015Publication date: June 15, 2017Inventors: Marcel MAIER, Jan GRIMM
-
Publication number: 20170166632Abstract: Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.Type: ApplicationFiled: October 27, 2016Publication date: June 15, 2017Inventors: Robert Joseph STAGG, Steven Eugene Benner
-
Publication number: 20170166633Abstract: The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind and neutralize RGM A protein. Specifically, these antibodies have the ability to inhibit the binding of RGM A to its receptor and/or coreceptors. These antibodies or portions thereof of the invention are useful for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but nor limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.Type: ApplicationFiled: December 23, 2016Publication date: June 15, 2017Inventors: Bernhard K. Mueller, Martin Schmidt, Eve Barlow, Mary Leddy, Chung-Ming Hsieh, Philip Bardwell
-
Publication number: 20170166634Abstract: The invention provides antibodies that specifically bind a P2X4 polypeptide and modulate P2X4 channel activity, recombinant P2X4 polypeptides and methods for generating such polypeptides, as well as compositions and methods for generating anti-P2X4 antibodies, and methods of using P2X4 antibodies for the treatment of neuropathic pain and other indications.Type: ApplicationFiled: May 2, 2015Publication date: June 15, 2017Applicant: Medimmune LimitedInventors: Wendy A WILLIAMS, Clare JONES, James BUTTON, John LINLEY, Harm Jan SNIJDER, Ling HUANG, Yoko SHIBATA, Sudharsan SRIDHARAN, Maria GROVES, Claire DOBSON
-
Publication number: 20170166635Abstract: Cysteine engineered anti-TENB2 antibodies are engineered by replacing one or more amino acids of a parent anti-TENB2 antibody with non cross-linked, reactive cysteine amino acids. Methods of design, preparation, screening, and selection of the cysteine engineered anti-TENB2 antibodies are provided. Cysteine engineered anti-TENB2 antibodies (Ab) are conjugated with one or more drug moieties (D) through a linker (L) to form cysteine engineered anti-TENB2 antibody-drug conjugates having Formula I: Ab-(L-D)p ??(I) where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.Type: ApplicationFiled: November 8, 2016Publication date: June 15, 2017Inventors: Weiguang Mao, Jagath Reddy Junutula, Paul Polakis
-
Publication number: 20170166636Abstract: The invention provides anti-LRP5 antibodies and methods of making and using the same.Type: ApplicationFiled: November 11, 2016Publication date: June 15, 2017Applicant: Genentech, Inc.Inventors: Yan Wu, Weilan Ye, Jeremy Bryant Burton, Cecilia Chiu
-
Publication number: 20170166637Abstract: The present invention provides compositions comprising anti-CEACAM1 antibodies, compositions comprising antibodies capable of inhibiting or blocking the interaction between PD-1 and its ligands, and methods for their combined use in treating cancer.Type: ApplicationFiled: November 25, 2014Publication date: June 15, 2017Applicant: CCAM BIOTHERAPEUTICS LTD.Inventors: Tehila BEN-MOSHE, Yair SAPIR, Ilana MANDEL, Edna MEILIN
-
Publication number: 20170166638Abstract: A polypeptide having a binding affinity to CD64 of at least 10?9 M for use in a treatment of a disease associated with an inflammation in combination with an anti-TNF-?, antibody.Type: ApplicationFiled: March 26, 2015Publication date: June 15, 2017Applicant: Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung e.V.Inventors: Dmitrij HRISTODOROV, Theophilus THEPEN, Stefan BARTH
-
Publication number: 20170166639Abstract: The present disclosure provides aldehyde-tagged immunoglobulin (Ig) polypeptides that can be converted by a formylglycine-generating enzyme to produce a 2-formylglycine (FGly)-modified Ig polypeptide. An FGly-modified Ig polypeptide can be covalently and site-specifically bound to a moiety of interest to provide an Ig conjugate. The disclosure also encompasses methods of production of such aldehyde-tagged Ig polypeptides, FGly-modified Ig polypeptides, and Ig conjugates, as well as methods of use of same.Type: ApplicationFiled: November 28, 2016Publication date: June 15, 2017Inventors: Robyn M. Barfield, Mark Alan Breidenbach, Gregory W. deHart, David Rabuka
-
Publication number: 20170166640Abstract: The invention relates to the use of CD89 activating molecules, in particular Fc alpha comprising molecules, and more particularly, IgA, for inducing apoptosis in neutrophils. Anti-CD89 antibodies can alternatively be used. The CD89 activation is beneficial in the treatment of various disorders associated with increases in neutrophils, such as autoimmune disorders, inflammatory disorders, NETosis, or cystic fibrosis.Type: ApplicationFiled: December 19, 2016Publication date: June 15, 2017Applicants: CSL BEHRING AG, UNIVERSITÄT BERNInventors: Stephan VON GUNTEN, Marc WEHRLI, Adrian ZÜRCHER, Sylvia MIESCHER
-
Publication number: 20170166641Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.Type: ApplicationFiled: February 3, 2015Publication date: June 15, 2017Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
-
Publication number: 20170166642Abstract: This disclosure relates to binding agents with specificity for programmed cell death 1 (PD-1) and to methods for using the same to treat, prevent and/or ameliorate an infectious disease (e.g., human immunodeficiency virus (HIV)), cancer and/or autoimmunity. In addition, this disclosure identifies a novel binding patch (“P2”) on PD-1 that is linked with a previously unidentified functional activity of PD-1 that is distinct from the interaction site involved with either the PD-L1 or PD-L2 ligands. Furthermore, we demonstrate that antibodies that interact with this region of PD-1 are able to act as antagonists of PD-1 and that this antagonism is further enhanced with the addition of antibodies that act through the blockade of the PD-1/PD-L1/L2 interaction.Type: ApplicationFiled: September 22, 2016Publication date: June 15, 2017Applicant: MabQuest SAInventors: Giuseppe Pantaleo, Craig Fenwick
-
Publication number: 20170166643Abstract: The invention relates to recombinant monovalent antibodies which are heterodimers of a first protein chain comprising the variable domain of the heavy chain of an antibody of interest and the CH2 and CH3 domains of an IgG immunoglobulin and a second protein chain comprising the variable domain of the light chain of said immunoglobulin of interest and the CH2 and CH3 domains of said IgG immunoglobulin. These antibodies can be used in particular as therapeutic agents in all cases where monovalent binding to a ligand such a cellular receptor is required.Type: ApplicationFiled: January 26, 2017Publication date: June 15, 2017Applicants: OSE Immunotherapeutics, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Bernard Vanhove, Caroline Mary, Flora Coulon
-
Publication number: 20170166644Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: ApplicationFiled: April 7, 2015Publication date: June 15, 2017Applicant: Sorrento Therapeutics, Inc.Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
-
Publication number: 20170166645Abstract: Methods are provided for targeting cells for depletion, including without limitation cancer cells, in a regimen comprising contacting the targeted cells with a combination of agents, including (i) an agent that blockades CD47 activity; and (ii) an antibody that specifically binds to EGFR. In some embodiments the cancer cells have a mutated form of one or more of KRAS, NRAS or BRAF. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single agent is used; and the effect may be synergistic relative to a regimen in which a single agent is used.Type: ApplicationFiled: December 8, 2016Publication date: June 15, 2017Inventors: Irving L. Weissman, Stephen Willingham, Doris Po Yi Ho, Piero D. Dalerba, Kelly Marie McKenna, Jens-Peter Volkmer
-
Publication number: 20170166646Abstract: The present invention provides compositions and methods of treating and improving the symptoms of uveitis and/or macular edema using an antibody that specifically binds human interleukin-6 receptor (hIL-6R).Type: ApplicationFiled: November 3, 2016Publication date: June 15, 2017Inventors: Preethi Aavali Sridhara Sundaram, Ronald Buggage, Karen W. Chu, Valérie Corp dit Genti, Kristine A. Erickson, Dominique Mery-Mignard, Rafael Varona, Robert L. Vitti
-
Publication number: 20170166647Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.Type: ApplicationFiled: November 21, 2016Publication date: June 15, 2017Applicant: Ablynx N.V.Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom